ABSTRACT
Aldo-Keto-Reductase 1C3 (type 5 17ß-hydroxysteroid dehydrogenase (HSD)/prostaglandin (PG) F2α synthase) is the only 17ß-HSD that is not a short-chain dehydrogenase/reductase. By acting as a 17-ketosteroid reductase, AKR1C3 produces potent androgens in peripheral tissues which activate the androgen receptor (AR) or act as substrates for aromatase. AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer (CRPC) and polycystic ovarian syndrome; and is implicated in the production of aromatase substrates in breast cancer. By acting as an 11-ketoprostaglandin reductase, AKR1C3 generates 11ß-PGF2α to activate the FP receptor and deprives peroxisome proliferator activator receptorγ of its putative PGJ2 ligands. These growth stimulatory signals implicate AKR1C3 in non-hormonal dependent malignancies e.g. acute myeloid leukemia (AML). AKR1C3 moonlights by acting as a co-activator of the AR and stabilizes ubiquitin ligases. AKR1C3 inhibitors have been used clinically for CRPC and AML and can be used to probe its pluripotency.
Subject(s)
Aldo-Keto Reductase Family 1 Member C3/metabolism , Endocrine Gland Neoplasms/enzymology , Endocrine System Diseases/enzymology , Aldo-Keto Reductase Family 1 Member C3/antagonists & inhibitors , Aldo-Keto Reductase Family 1 Member C3/chemistry , Aldo-Keto Reductase Family 1 Member C3/genetics , Endocrine Gland Neoplasms/genetics , Endocrine System Diseases/genetics , Enzyme Inhibitors/pharmacology , Epigenesis, Genetic/drug effects , Humans , Steroids/biosynthesisABSTRACT
Various molecular and cellular alterations of the cyclic adenosine monophosphate (cAMP) pathway have been observed in endocrine tumors. Since protein kinase A (PKA) is a central key component of the cAMP pathway, studies of the alterations of PKA subunits in endocrine tumors reveal new aspects of the mechanisms of cAMP pathway alterations in human diseases. So far, most alterations have been observed for the regulatory subunits, mainly PRKAR1A and to a lower extent, PRKAR2B. One of the best examples of such alteration today is the multiple neoplasia syndrome Carney complex (CNC). The most common endocrine gland manifestations of CNC are pituitary GH-secreting adenomas, thyroid tumors, testicular tumors, and ACTH-independent Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD). Heterozygous germline inactivating mutations of the PKA regulatory subunit RIα gene (PRKAR1A) are observed in about two-third of CNC patients, and also in patients with isolated PPNAD. PRKAR1A is considered as a tumor suppressor gene. Interestingly, these mutations can also be observed as somatic alterations in sporadic endocrine tumors. More than 120 different PRKAR1A mutations have been found today. Most of them lead to an unstable mutant mRNA, which will be degraded by nonsense mediated mRNA decay. In vitro and in vivo functional studies are in progress to understand the mechanisms of endocrine tumor development due to PKA regulatory subunits inactivation. PRKAR1A mutations stimulate in most models PKA activity, mimicking in some way cAMP pathway constitutive activation. Cross-talks with other signaling pathways summarized in this review have been described and might participate in endocrine tumorigenesis.
Subject(s)
Cyclic AMP-Dependent Protein Kinases/genetics , Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/genetics , Mutation/genetics , Adrenal Cortex/pathology , Animals , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Endocrine Gland Neoplasms/drug therapy , Endocrine Gland Neoplasms/pathology , Humans , Molecular Targeted Therapy , Protein Subunits/antagonists & inhibitors , Protein Subunits/geneticsABSTRACT
BACKGROUND: Kinases represent potential therapeutic targets in pancreatic endocrine tumours (PETs). PATIENTS AND METHODS: Thirty-five kinase genes were sequenced in 36 primary PETs and three PET cell lines: (i) 4 receptor tyrosine kinases (RTK), epithelial growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), tyrosine-protein kinase KIT (KIT), platelet-derived growth factor receptor alpha (PDGFRalpha); (ii) 6 belonging to the Akt/mTOR pathway; and (iii) 25 frequently mutated in cancers. The immunohistochemical expression of the four RTKs and the copy number of EGFR and HER2 were assessed in 140 PETs. RESULTS: Somatic mutations were found in KIT in one and ATM in two primary neoplasms. Among 140 PETs, EGFR was immunopositive in 18 (13%), HER2 in 3 (2%), KIT in 16 (11%), and PDGFRalpha in 135 (96%). HER2 amplification was found in 2/130 (1.5%) PETs. KIT membrane immunostaining was significantly associated with tumour aggressiveness and shorter patient survival. PET cell lines QGP1, CM and BON harboured mutations in FGFR3, FLT1/VEGFR1 and PIK3CA, respectively. CONCLUSIONS: Only rare PET cases, harbouring either HER2 amplification or KIT mutation, might benefit from targeted drugs. KIT membrane expression deserves further attention as a prognostic marker. ATM mutation is involved in a proportion of PET. The finding of specific mutations in PET cell lines renders these models useful for preclinical studies involving pathway-specific therapies.
Subject(s)
Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/genetics , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/genetics , Protein Kinases/genetics , Cell Line, Tumor , DNA Mutational Analysis , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Mutation , Protein Kinases/metabolism , Tissue Array AnalysisABSTRACT
Phosphodiesterases (PDEs) are enzymes that regulate the intracellular levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate, and, consequently, exhibit a central role in multiple cellular functions. The pharmacological exploitation of the ability of PDEs to regulate specific pathways has led to the discovery of drugs with selective action against specific PDE isoforms. Considerable attention has been given to the development of selective PDE inhibitors, especially after the therapeutic success of PDE5 inhibitors in the treatment of erectile dysfunction. Several associations between PDE genes and genetic diseases have been described, and more recently PDE11A and PDE8B have been implicated in predisposition to tumor formation. This review focuses on the possible function of PDEs in a variety of tumors, primarily in endocrine glands, both in tumor predisposition and as potential therapeutic targets.
Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/metabolism , 3',5'-Cyclic-GMP Phosphodiesterases/metabolism , Antineoplastic Agents/therapeutic use , Endocrine Cells/enzymology , Endocrine Gland Neoplasms/drug therapy , Phosphodiesterase Inhibitors/therapeutic use , 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , 3',5'-Cyclic-GMP Phosphodiesterases/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cyclic AMP/antagonists & inhibitors , Cyclic AMP/physiology , Cyclic GMP/antagonists & inhibitors , Cyclic GMP/physiology , Endocrine Cells/drug effects , Endocrine Cells/metabolism , Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/metabolism , Humans , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Molecular Targeted Therapy , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/metabolism , Phosphodiesterase Inhibitors/pharmacologyABSTRACT
Carney complex (CNC) is a rare multiple familial neoplasia syndrome that is characterized by multiple types of skin tumors and pigmented lesions, endocrine neoplasms, myxomas and schwannomas and is inherited in an autosomal dominant manner. Clinical and pathologic diagnostic criteria are well established. Over 100 pathogenic variants in the regulatory subunit type 1A (RI-A) of the cAMP-dependent protein kinase (PRKAR1A) have been detected in approximately 60% of CNC patients, most leading to R1A haploinsufficiency. Other CNC-causing genes remain to be identified. Recent studies provided some genotype-phenotype correlations in CNC patients carrying PRKAR1A-inactivating mutations, which provide useful information for genetic counseling and/or prognosis; however, CNC remains a disease with significant clinical heterogeneity. Recent mouse and in vitro studies have shed light into how R1A haploinsufficiency causes tumors. PRKAR1A defects appear to be weak tumorigenic signals for most tissues; Wnt signaling activation and cell cycle dysregulation appear to be important mediators of the tumorigenic effect of a defective R1A.
Subject(s)
Carney Complex/genetics , Endocrine Gland Neoplasms/genetics , Myxoma/genetics , Neurilemmoma/genetics , Skin Neoplasms/genetics , Animals , Carney Complex/enzymology , Carney Complex/pathology , Cyclic AMP-Dependent Protein Kinase RIalpha Subunit/genetics , Disease Models, Animal , Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/pathology , Germ-Line Mutation/genetics , Haploinsufficiency/genetics , Humans , Mice , Myxoma/enzymology , Myxoma/pathology , Neurilemmoma/enzymology , Neurilemmoma/pathology , Skin Neoplasms/enzymology , Skin Neoplasms/pathology , Wnt Proteins/geneticsABSTRACT
Tumor necrosis factor alpha converting enzyme (TACE) mediates shedding of human epidermal growth factor receptor-4 (HER4). Recent data suggest that released HER4 intracellular domain (4ICD) induces apoptosis in breast cancer. TACE expression, as measured by immunohistochemical analysis, was observed in 183 of 383 breast carcinomas, 39 of 217 ovarian carcinomas, and 16 of 24 and 17 of 24 hormonesensitive and hormone-insensitive prostate carcinomas, respectively. HER4 expression was detected in breast carcinomas by using 2 antibodies recognizing an extracellular or intracellular epitope. TACE expression was predominantly seen in tumors with high levels of 4ICD and membranous HER4. Apoptotic activity was measured by the terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay and cleaved caspase-3 staining in breast carcinomas. There was no significant association between cleaved caspase-3 or TUNEL positivity and 4ICD, whereas TUNEL positivity was seen predominantly in tumors with high levels of internalized HER4. The data presented herein show TACE expression in endocrine cancers and further support a role for TACE in breast cancer apoptosis.
Subject(s)
ADAM Proteins/biosynthesis , Breast Neoplasms/enzymology , Endocrine Gland Neoplasms/enzymology , Ovarian Neoplasms/enzymology , Prostatic Neoplasms/enzymology , ADAM17 Protein , Apoptosis/physiology , Breast Neoplasms/pathology , Endocrine Gland Neoplasms/pathology , ErbB Receptors/biosynthesis , Female , Gene Expression , Humans , In Situ Nick-End Labeling , Male , Ovarian Neoplasms/pathology , Prostatic Neoplasms/pathology , Receptor, ErbB-4 , Receptors, Estrogen/biosynthesisABSTRACT
Most solid tumours preferentially develop glycolytic metabolism, often accompanying tumor aggressiveness. Increase in nucleic acid synthesis is associated with cell proliferation and glucose shunting to the pentose phosphate pathway. High glucose consumption is more associated with a metabolic adaptation than with a mitochondrial defect. Tumor cells do not present specific genetic modifications but adapt their metabolic capacities to their priority needs. However their metabolisms depend on oncogene expression more specifically expressed in this context. The glycolytic pathway is favored by tumor proliferation under hypoxia. Stabilization of HIF1 factor may explain the glycolytic metabolism of the tumors in an anaerobic environment. We demonstrate in two types of mitochondrial rich tumors, that specific defects induce completely different metabolic directions: when familial paragangliomas present a glycolytic metabolism, thyroid oncocytic tumors develop a specific oxidative metabolism.
Subject(s)
Endocrine Gland Neoplasms/metabolism , Energy Metabolism/physiology , Mitochondria/metabolism , Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/pathology , Endocrine Gland Neoplasms/ultrastructure , Gluconeogenesis/physiology , Glucose/metabolism , Glycolysis/physiology , Humans , Mitochondria/enzymology , Mitochondria/pathology , Pentose Phosphate PathwayABSTRACT
Prostaglandins (PG) are members of a large group of hormonally active fatty acids derived from free fatty acids. They are formed from arachidonic acid-the major PG precursor. Cyclooxygenase (COX)-1 and -2 are the rate-limiting steps in PG synthesis. COX-2 is overexpressed in many human non-endocrine and endocrine tumors including colon, breast, prostate, brain, thyroid, and pituitary. COX-2 has an important role in angiogenesis and tumor growth. Thromboxane synthase (TS) catalyzes the synthesis of thromboxane A2 (TXA2), which is derived from arachidonic acid and prostaglandin H2 and is a vasoconstrictor and inducer of platelet aggregation. TXA2 stimulates tumor growth and spread of some tumors and TS appears to have a critical role in tumorigenesis in some organ systems. In this review, we examine the role of COX-2 and TS in various non-endocrine tumors, especially colon, breast, prostate, and brain as well as in endocrine tumors. The accumulating evidence points to an increasingly important role of COX-2 and TS in tumor progression and metastasis.
Subject(s)
Cyclooxygenase 2/metabolism , Endocrine Gland Neoplasms/enzymology , Neoplasms/enzymology , Prostaglandins/metabolism , Thromboxane-A Synthase/metabolism , Animals , Female , Humans , MaleABSTRACT
BACKGROUND: Inactivation of the human type Ialpha regulatory subunit (RIalpha) of cyclic AMP dependent protein kinase (PKA) (PRKAR1A) leads to altered kinase activity, primary pigmented nodular adrenocortical disease (PPNAD), and sporadic adrenal and other tumours. METHODS AND RESULTS: A transgenic mouse carrying an antisense transgene for Prkar1a exon 2 (X2AS) under the control of a tetracycline responsive promoter (the Tg(Prkar1a*x2as)1Stra, Tg(tTAhCMV)3Uh or tTA/X2AS line) developed thyroid follicular hyperplasia and adenomas, adrenocortical hyperplasia and other features reminiscent of PPNAD, including late onset weight gain, visceral adiposity, and non-dexamethasone suppressible hypercorticosteronaemia, with histiocytic, epithelial hyperplasias, lymphomas, and other mesenchymal tumours. These lesions were associated with allelic losses of the mouse chromosome 11 Prkar1a locus, an increase in total type II PKA activity, and higher RIIbeta protein levels; the latter biochemical and protein changes were also documented in Carney complex tumours associated with PRKAR1A inactivating mutations and chromosome 17 PRKAR1A locus changes. CONCLUSION: We conclude that the tTA/X2AS mouse line with a downregulated Prkar1a gene replicates several of the findings in Carney complex patients and their affected tissues, supporting the role of RIalpha as a candidate tumour suppressor gene.
Subject(s)
Endocrine Gland Neoplasms/enzymology , Proteins/physiology , Adrenal Cortex Diseases/enzymology , Adrenal Cortex Diseases/genetics , Adrenal Gland Neoplasms/enzymology , Adrenal Gland Neoplasms/genetics , Alleles , Animals , Cyclic AMP-Dependent Protein Kinase RIalpha Subunit , Cyclic AMP-Dependent Protein Kinase Type II , Cyclic AMP-Dependent Protein Kinases/metabolism , Down-Regulation , Endocrine Gland Neoplasms/genetics , Gene Deletion , Genes, Tumor Suppressor , Humans , Loss of Heterozygosity , Mice , Mice, Transgenic , Mutation , Neoplastic Syndromes, Hereditary/enzymology , Neoplastic Syndromes, Hereditary/genetics , Phenotype , Proteins/genetics , Thyroid Neoplasms/enzymology , Thyroid Neoplasms/geneticsABSTRACT
Cyclooxygenase (COX) is a key rate-limiting enzyme in prostaglandin biosynthesis. There are two isoforms of COX, referred to as COX-1 and COX-2. COX-2, an inducible form of COX, is found to be overexpressed in various neoplasms and is believed to play an important role in tumorigenesis and tumor development. In this study, we investigated expression of the COX-2 protein in human endocrine tumors of the pancreas (N=23; 6 insulinomas, one glucagnoma, 2 gastrinomas, and 14 non-functioning tumors) using immunohistochemistry. Strong COX-2 expression was confirmed in normal islet tissue as previously reported. COX-2 immunoreactivity was detected in 65% (15 out of 23) of these tumors with a moderate to strong intensity. In all nine functioning tumors, COX-2 expressions were preserved with the weak or strong intensity. In contrast, COX-2 was present in 6 out of 14 nonfunctioning tumors. The correlation between COX-2 expression and their function was significant (p<0.05). We found that expression of this enzyme was detected in 11 out of 15 benign tumors and in 4 out of 8 malignant tumors, respectively. Our results suggest that COX-2 may play an important role in the endocrine function of islet tumors. Additionally, malignancy was not related to COX-2 expression.
Subject(s)
Endocrine Gland Neoplasms/enzymology , Isoenzymes/metabolism , Pancreatic Neoplasms/enzymology , Prostaglandin-Endoperoxide Synthases/metabolism , Adult , Aged , Cyclooxygenase 2 , Endocrine Gland Neoplasms/pathology , Endocrine Gland Neoplasms/surgery , Female , Humans , Immunohistochemistry , Male , Membrane Proteins , Middle Aged , Neoplasm Invasiveness , Neoplasm Metastasis , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgeryABSTRACT
Telomerase, the ribonucleoprotein enzyme that elongates chromosomal ends, or telomeres, is repressed in most normal somatic cells but reactivated in transformed cells to compensate for the progressive erosion of the telomeres during cell divisions. In accordance with this hypothesis, the presence of telomerase activity has been reported in more than 90% of human cancers, whereas most normal tissues or benign tumors contain low or undetectable telomerase activity. Reactivation of telomerase has also been widely reported in endocrine neoplasms and in hormone-related cancers. In the present study, we review the most recent publications on telomerase in these types of tumors. The hormonal regulation of telomerase activity and the possible strategies for cancer therapy based on the inhibition of telomerase has also been discussed.
Subject(s)
Endocrine Gland Neoplasms/enzymology , Neoplasms, Hormone-Dependent/enzymology , Telomerase/metabolism , Adrenal Gland Neoplasms/enzymology , Biomarkers, Tumor/analysis , Breast Neoplasms/enzymology , Endocrine Gland Neoplasms/therapy , Female , Humans , Male , Neoplasms, Hormone-Dependent/therapy , Neuroblastoma/enzymology , Neuroendocrine Tumors/enzymology , Parathyroid Neoplasms/enzymology , Pheochromocytoma/enzymology , Prostatic Neoplasms/enzymology , Thyroid Neoplasms/enzymologySubject(s)
Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP/metabolism , Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/genetics , Signal Transduction , Cushing Syndrome/enzymology , Cushing Syndrome/metabolism , Cushing Syndrome/pathology , Cyclic AMP-Dependent Protein Kinases/genetics , Endocrine Gland Neoplasms/metabolism , Endocrine Gland Neoplasms/pathology , Genetic Predisposition to Disease , Humans , Mutation/genetics , Myxoma/enzymology , Myxoma/genetics , Myxoma/metabolism , Myxoma/pathology , Pigmentation Disorders/enzymology , Pigmentation Disorders/metabolism , SyndromeABSTRACT
Telomeres representing repetitive DNA sequences of chromosome ends are necessary for maintaining chromosomal integrity. The enzyme telomerase synthesizes de novo telomeric repeats and incorporates them onto the DNA 3'-ends of chromosomes. Stability of chromosome ends and activation of telomerase are elementary requirements for cell immortalization and tumor progression. The telomeric length and telomerase activity have been recently studied in several human neoplasms, including those of endocrine tissues. Assessment of telomerase activity may help to distinguish normal or hyperplastic from neoplastic tissues. Inhibition or inactivation of telomerase activity may provide novel strategies for cancer therapy.
Subject(s)
Endocrine Gland Neoplasms/enzymology , Endocrine Gland Neoplasms/ultrastructure , Endocrine Glands/enzymology , Endocrine Glands/ultrastructure , Telomerase/metabolism , Telomere , Animals , Antineoplastic Agents , Humans , Telomerase/antagonists & inhibitorsABSTRACT
We have examined concentrations of neurone-specific enolase (NSE) in sera from 18 patients with various neuroendocrine tumours, 26 patients with carcinoid tumours, 21 patients with non-neuroendocrine tumours and 37 control individuals. No statistically significant difference between the concentrations in patients with neuroendocrine tumours and patients with carcinoid tumours was found. However the NSE concentrations in patients with carcinoid and neuroendocrine tumours, when these two groups were combined, were significantly different from the patients with non-neuroendocrine tumours or the control individuals (P < or = 0.01). 38.5% of the patients with carcinoid tumours had raised NSE concentrations in serum; 55.5% of those with non carcinoid neuroendocrine tumours had raised concentrations. There appeared to be no correlation between the NSE concentrations and the extent of metastases.
Subject(s)
Carcinoid Tumor/enzymology , Endocrine Gland Neoplasms/enzymology , Nervous System Neoplasms/enzymology , Phosphopyruvate Hydratase/blood , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
Neuron-specific enolase (NSE), the glycolytic isoenzyme of the enolase gamma-gamma dimer, is a specific marker for the diffuse neuroendocrine system and derivative tumors (NET). Serum levels of NSE were measured in 39 patients with NET of the gastrointestinal tract (including 3 gastric and 13 intestinal carcinoid tumors, 6 gastrinomas, 3 insulinomas, 1 glucagonoma, 2 mixed islet cell tumors, 11 neuroendocrine pancreatic carcinomas), in 15 healthy subjects and in 15 nonendocrine gastric, pancreatic, and intestinal tumors. Thirty-six of the 39 patients had elevated circulating levels of NSE, 2 insulinomas and 1 gastrinoma had values below 12 ng/ml like healthy subjects and nonendocrine tumors. No significant difference of serum NSE was found between 23 'functioning' and 16 'nonfunctioning' NET. Fourteen of the NET were malignant, and NSE circulating values were significantly higher than those of nonmalignant forms. After curative surgery serum NSE decreased significantly. NSE can be considered a reliable marker in the differential diagnosis between endocrine and nonendocrine neoplasms, in the clinical detection of silent endocrine tumors and in the follow-up of NET.